Xiaofeng Chen, Xiang Xu, Danping Wang, Jinyuan Liu, Jing Sun, Mingjie Lu, Rui Wang, Bingqing Hui, Xiaofei Li, Chenchen Zhou, Min Wang, Tianzhu Qiu, Shiyun Cui, Nana Sun, Yang Li, Fufeng Wang, Cuicui Liu, Yang Shao, Jinhua Luo, Yanhong Gu
BACKGROUND: The standard neoadjuvant treatments in patients with esophageal squamous cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed in China. METHODS: This was an open-label, single-arm, phase 2 trial. Patients with potentially resectable ESCC (cT1b-3, Nany, M0 or T4a, N0-1, or M0) received preoperative intravenous sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles...
February 2023: Journal for Immunotherapy of Cancer